NervGen Pharma Announces Clinical Development Plan For the Treatment of Nerve Damage and Neurodegenerative Diseases / NervGen Reports Results of Annual General Meeting of Shareholders
Vancouver, Canada. September 6, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis. […]
NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
Vancouver, Canada. July 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen’s core Intracellular Sigma Peptide (“ISP”) technology in a mouse […]
NervGen Grants Stock Option Shares for Investor Relations Consulting Services
Vancouver, Canada. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company granted an aggregate of 50,000 shares of stock options as part of an agreement for investor […]
NervGen Amends Investor Relations Agreement
Vancouver, Canada. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 […]
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination / Lead Indication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial
Vancouver, Canada. June 26, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond spinal cord injury to multiple sclerosis (“MS”), another […]
NervGen Pharma Announces Upgrade to the OTCQX® Best Market in the U.S.
Vancouver, Canada. June 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market (“OTCQX”). NervGen upgraded […]
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
Vancouver, Canada. June 4, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma’s President & CEO, will be presenting at the 9th […]
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
Vancouver, Canada. June 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. (“Torrey Hills Capital”) […]
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing / Paul Brennan Joins NervGen Pharma as Business Advisor
Vancouver, Canada. May 30, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company’s Vice President, Chemistry, Manufacturing […]
NervGen Pharma Commences Trading on OTCQB / NervGen Pharma Engages Market Maker
Vancouver, Canada. May 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will […]